DS’den Kovid-19 iin yeni ila nerisi


In the written statement from the organization, the recommendations of the DS International Standards Development Group of Experts on the effectiveness of joint inflammation drugs against Kovid-19, after 7 separate trials on approximately 4,000 patients with mild, severe and critical conditions, were included. .

Accordingly, it was determined that joint inflammation drugs Baricitinib and Interleukin-6 (IL-6) had a positive effect on the recovery of Kovid-19 patients in severe condition when used together with corticosteroid medication.

While the resistance to virus of the patients who were given these drugs increased, the need for oxygen therapy decreased.

Experts warned that these two drugs should never be used at the same time.

For patients whose condition was not severe, the use of Sotrovimab, one of the monoclonal antibody drugs, was recommended “under certain conditions”.

In clinical trials, the use of Ruxolitinib and Tofacitinib, which are also joint inflammation drugs, resulted in improvement in patients, but it was stated that sufficient evidence was not obtained against new variants of Kovid-19 such as Omicron, and their use was not recommended.

It was noted that new information about the monoclonal antibody drug, one of which was decided to be a conditional recommendation for now, will be shared when the trial results are announced.

DS experts have previously made a conditional recommendation for the use of IL-6 in severe and critical Covid-19 patients.

– WARNING FROM MFS FOR LALARDA PATENT MONOPOLY

Following the recommendation of the World Health Organization regarding the use of Baricitinib and IL-6, in the statement made by the Doctors Without Borders (MFS) organization, it was stated that monopoly should be avoided in the recommended drugs.

MFS Infectious Diseases Medical Advisor Dr. Noting that absolute access for patients in low- and middle-income countries to DS-recommended drugs is vital, Marcio da Fonseca said, “In order to ensure adequate, timely and equitable access to drugs and to avoid patent monopoly, states must waive the Trade Linked Intellectual Property Agreement.” and should encourage the adoption of practices such as compulsory licensing. made its assessment.

Emphasizing that people in middle and low-income countries are in fear due to insufficient employment rate and new variants that continue to affect their effects, Da Fonseca stated that global equality should be ensured in access to means of combating the epidemic.


Source: STAR.COM.TR by www.star.com.tr.

*The article has been translated based on the content of STAR.COM.TR by www.star.com.tr. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!